tirzepatide mechanism of action and other GLP1RA as a novel treatment for patients with congenital generalized lipodystrophy Tirzepatide: A dual action approach

In China, public and clinical awareness of GLP-1 therapies for overweight and obesity had emerged prior to the approval of Wegovy and Mounjaro and was further strengthened following the drugs mid-2024 approvals for chronic weight management

Discuss at your next appointment if: you have reached week 8 with zero noticeable appetite or weight changes at your current dose, side effects are manageable but annoying and not improving, you are considering adjusting your dose escalation timeline, you want to explore combination approaches, or you are experiencing insomnia , menstrual changes , feeling unusually cold , or hormonal changes that you suspect are related to the medication

S.RidnourL

Your 100mg vial may contain enough peptide for 100 days, but once reconstituted, the solution only remains stable for approximately 21-30 days